Form 4: Absci Corp Executive Todd Bedrick Reports Acquisition of Shares and Stock Options

Todd Bedrick, SVP, CAO of Absci Corp, reports the acquisition of 29,700 shares of common stock and 117,300 stock options.

Summary

• On March 3, 2025, Todd Bedrick, SVP, CAO of Absci Corp, reported acquiring 29,700 shares of common stock through Restricted Stock Units (RSUs) and 117,300 stock options.
• The RSUs vest in three substantially equal annual installments starting March 3, 2026, contingent upon continuous service.
• The stock options also vest in three substantially equal annual installments starting March 3, 2026, contingent upon continuous service, and have an exercise price of $3.42.
• Following these transactions, Bedrick directly owns 167,827 shares of Absci Corp common stock and 117,300 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options by an executive is generally viewed as a positive sign, but it's not a strong indicator of future performance.

Positives

• The acquisition of shares and options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both the RSUs and stock options incentivize long-term commitment from the executive.

Future Outlook

The vesting schedules for the RSUs and stock options suggest an expectation of continued service and contribution from the executive over the next three years.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to align management's interests with those of shareholders.
• Vesting schedules of three years are typical for such grants, encouraging long-term commitment.
• Comparing the size of the grant to those of executives at comparable companies (e.g., other biotech firms with similar market capitalization) would provide further context.

Stakeholder Impact

• Shareholders may view the executive's increased stake in the company as a positive signal.
• Employees may see it as a sign of confidence in the company's future.

Key Dates